The gross margin surge to 101.8% in 2026Q2, from 64.6% in 2024Q4, indicates a favorable product mix shift toward Attruby sales, but this has not translated into operating profitability. Operating margin improved from -120.1% in 2025Q4 to -51.4% in 2026Q2, suggesting early operating leverage, yet the absolute losses remain substantial. Net margin of -73.0% in 2026Q2, while improved from -127.9% in 2025Q4, still reflects significant non-operating charges and the high fixed-cost base of the hub-and-spoke model. Investors should monitor whether the pace of margin expansion can outpace the escalating SG&A and R&D costs as the commercial organization scales.

The cash conversion cycle (CCC) has been highly erratic, ranging from -452 days in 2025Q1 to +56 days in 2026Q1, with DSO spiking to 100 days in 2026Q2 and DPO fluctuating widely. This volatility suggests that milestone payments and supplier terms are creating large swings in working capital, masking the underlying cash burn. Asset turnover remains low at 0.16 in 2026Q2, reflecting the asset-light model where revenue is still small relative to the balance sheet base. The negative DIO in 2026Q2 (-1055 days) is likely an artifact of inventory accounting, but it underscores the need to focus on normalized cash burn rather than quarterly working capital movements.

The current ratio has deteriorated sharply from 4.67 in 2024Q4 to 1.15 in 2026Q2, as current liabilities have grown with the commercial build-out while cash has remained relatively flat. The quick ratio of 1.09 in 2026Q2 suggests that inventory is not a major liquidity concern, but the rapid decline in the current ratio indicates that the company is becoming more reliant on near-term cash flows to meet obligations. With a quarterly cash burn of approximately $71.5M in FCF in 2026Q2, the current cash position of $677.9M provides roughly 9-10 quarters of runway, assuming no additional financing. However, the negative equity of -$2.5B and the need to fund ongoing losses suggest that external capital will be required before reaching break-even, which may lead to further dilution.

The dramatic reduction in total debt from $3.4B in 2026Q1 to $18.3M in 2026Q2 appears to reflect a major refinancing event, possibly a conversion of debt into equity, which would explain the deepening negative equity. While this reduces immediate interest expense and improves the debt-to-equity ratio on paper, the negative shareholders' equity of -$2.5B indicates that the company is still highly leveraged in a structural sense. Interest coverage remains negative at -1.35 in 2026Q2, meaning operating income is insufficient to cover interest costs, though the low debt level now reduces this risk. Investors should monitor the terms of any new financing, as the company's reliance on capital markets to fund operations suggests that future dilution or debt issuance is likely.

BridgeBio's price-to-sales multiple of 33.03 is substantially higher than the peer group, including Vertex at ~9.5 and Ultragenyx at ~4.6, indicating that the market is pricing in a rapid revenue ramp for Attruby. However, the company's negative ROE and ROIC, which are in line with loss-making peers like Kymera and Arcus, suggest that the premium is based on future potential rather than current profitability. The gross margin of 101.8% is superior to most peers, reflecting the high-margin nature of rare disease drugs, but the operating margin of -51.4% is worse than some peers, indicating that the commercial infrastructure is still being built. The gap in profitability metrics may narrow if Attruby continues to gain market share, but the current valuation leaves little room for disappointment.